Analysts echoed investor enthusiasm, with H.C. Wainwright increasing its price target from $6.70 to $8 and BMO Capital Markets boosting its target from $6 to $8.
Here’s what they had to say.
The FDA label expands Tavalisse’s addressable population to second-line, steroid-refractory patients, and it places the drug in competition with thrombopoietin-receptor agonists, including Amgen, Inc. (NASDAQ: AMGN)’s Nplate and Novartis AG (ADR) (NYSE: AVS)’s Promacta.
“We believe it may be priced close to current therapies (we project $100K annual cost per year),” H.C. Wainwright analysts Joseph Pantginis and Pete Stavropoulos wrote in a note.
Notably, BMO considers the option advantageous above — although clinically inferior to — thrombopoietin alternatives for its simple administration.
At the same time, the candidate has enduring opportunities in other indications.
“We expect additional upside to come from greater use in earlier treatment lines and accelerated development in AIHA [autoimmune hemolytic anemia],” BMO analyst Do Kim wrote in a note. “We believe a similar label for AIHA could nearly double our Tavalisse peak sales estimate to $1.1 billion.”
Rigel expects a late-May launch in the U.S. and fourth-quarter filing in the EU ahead of signing an international partnership, which BMO predicts will unlock additional upside.
Upcoming catalysts include a pipeline expansion with R835 and approval of fostamatinib, the latter of which is only partially priced into the stock, according to H.C. Wainwright.
At time of publication, the stock had conceded a portion of its gains to trade down 2.9 percent off Tuesday’s closing price at $3.99.
Rigel Pharmaceuticals Q4 Earnings Outlook
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
Latest Ratings for RIGL
|Apr 2018||BMO Capital||Maintains||Outperform||Outperform|
|Apr 2018||H.C. Wainwright||Maintains||Buy||Buy|
|Dec 2017||Cantor Fitzgerald||Initiates Coverage On||Overweight|
View More Analyst Ratings for RIGL
View the Latest Analyst Ratings
See more from Benzinga
- Quicken Loans Breaks Down What Goes Into A Perfect Ad
- Tesla's Plant Shutdowns, Model 3 Prospects, Q1 Earnings: What Analysts Are Saying
- Healthcare Services Frail On Client Credit Deterioration, Stifel Says In Downgrade
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.